Schedule of Disaggregated Revenue |
The Company's significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for each of the three months ended March 31, 2020 and 2019 are set forth below (in thousands):
|
|
|
Three Months Ended March 31, |
|
|
|
|
2020 |
|
|
2019 |
|
Generics |
|
|
|
|
|
|
|
|
|
|
Anti-Infective |
|
$ |
13,253 |
|
|
$ |
5,942 |
|
|
Hormonal/Allergy |
|
|
87,481 |
|
|
|
102,725 |
|
|
Antiviral |
|
|
15,824 |
|
|
|
14,456 |
|
|
Central Nervous System (1) |
|
|
101,575 |
|
|
|
124,775 |
|
|
Cardiovascular System |
|
|
29,679 |
|
|
|
36,217 |
|
|
Gastroenterology |
|
|
23,536 |
|
|
|
9,556 |
|
|
Oncology |
|
|
15,966 |
|
|
|
14,959 |
|
|
Metabolic Disease/Endocrine |
|
|
17,229 |
|
|
|
17,847 |
|
|
Respiratory |
|
|
10,067 |
|
|
|
9,218 |
|
|
Dermatology |
|
|
15,245 |
|
|
|
12,973 |
|
|
Other therapeutic classes |
|
|
21,746 |
|
|
|
18,177 |
|
|
International and other |
|
|
985 |
|
|
|
15,632 |
|
|
Total Generics net revenue |
|
|
352,586 |
|
|
|
382,477 |
|
Specialty |
|
|
|
|
|
|
|
|
|
|
Hormonal/Allergy |
|
|
13,954 |
|
|
|
10,899 |
|
|
Central Nervous System (1) |
|
|
68,311 |
|
|
|
42,899 |
|
|
Gastroenterology |
|
|
48 |
|
|
|
481 |
|
|
Metabolic Disease/Endocrine |
|
|
273 |
|
|
|
541 |
|
|
Other therapeutic classes |
|
|
5,391 |
|
|
|
8,823 |
|
|
Total Specialty net revenue |
|
|
87,977 |
|
|
|
63,643 |
|
AvKARE |
|
|
|
|
|
|
|
|
|
|
Distribution |
|
|
31,586 |
|
|
|
— |
|
|
Government Label |
|
|
21,378 |
|
|
|
— |
|
|
Institutional |
|
|
3,413 |
|
|
|
— |
|
|
Other |
|
|
1,593 |
|
|
|
— |
|
|
Total AvKARE net revenue |
|
|
57,970 |
|
|
|
— |
|
|
Total net revenue |
|
$ |
498,533 |
|
|
$ |
446,120 |
|
|
(1) |
During the three months ended September 30, 2019, operating results for Oxymorphone were reclassified from Generics to Specialty, where it is sold as a non-promoted product. Prior period results have not been restated to reflect the reclassification. |
|
Schedule of Major Categories of Sales-Related Deductions |
A rollforward of the major categories of sales-related deductions for the three months ended March 31, 2020 is as follows (in thousands):
|
|
Contract
Charge - Backs
and Sales
Volume
Allowances |
|
|
Cash Discount
Allowances |
|
|
Accrued
Returns
Allowance |
|
|
Accrued
Medicaid and
Commercial
Rebates |
|
Balance at December 31, 2019 |
|
$ |
829,807 |
|
|
$ |
34,308 |
|
|
$ |
150,361 |
|
|
$ |
114,960 |
|
Impact from the Acquisitions |
|
|
15,292 |
|
|
|
944 |
|
|
|
15,229 |
|
|
|
10 |
|
Provision related to sales recorded in the period |
|
|
1,080,290 |
|
|
|
32,947 |
|
|
|
47,163 |
|
|
|
36,472 |
|
Credits/payments issued during the period |
|
|
(1,244,302 |
) |
|
|
(35,371 |
) |
|
|
(26,301 |
) |
|
|
(40,067 |
) |
Balance at March 31, 2020 |
|
$ |
681,087 |
|
|
$ |
32,828 |
|
|
$ |
186,452 |
|
|
$ |
111,375 |
|
|